[Vasopeptidase inhibition: a new pharmacological principle in the treatment of hypertension and cardiac insufficiency].
Kolloch
R
R
Medizinische Klinik, Krankenanstalten Gilead, Bielefeld. kolloch@gilead.de
Offers
E
E
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D009320:Atrial Natriuretic Factor / Q000494:pharmacology* / Q000502:physiology; D001794:Blood Pressure / Q000187:drug effects*; D004730:Endothelium, Vascular / Q000378:metabolism; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D015260:Neprilysin / Q000037:antagonists & inhibitors*; D011945:Receptors, Angiotensin / Q000378:metabolism; D012084:Renin-Angiotensin System / Q000187:drug effects / Q000502:physiology
D000806:Angiotensin-Converting Enzyme Inhibitors; D011945:Receptors, Angiotensin; D009320:Atrial Natriuretic Factor; D015260:Neprilysin